DESTINY-Breast03 Phase 3 Study Results
Baseline Characteristics
Hormone receptor-positive
T-DXD
(n=331)
TPC
(n = 163)
Age, median (range), years
57 (32-80)
56 (28-80)
T-DXd
(n=373)
58 (32-80)
DESTINY-Breast04
All patients
TPC
(n = 184)
56 (28-80)
Female, n (%)
Region, n (%)
Europe + Israel
Asia
329 (99)
163 (100)
371 (99)
184 (100)
149 (45)
73 (45)
166 (45)
85 (46)
128 (39)
60 (37)
147 (39)
66 (36)
54 (16)
30 (18)
60 (16)
33 (18)
North America
HER2 status (IHC), n (%)
193 (58)
95 (58)
215 (58)
106 (58)
1+
138 (42)
68 (42)
158 (42)
78 (42)
2+/ISH-
ECOG performance status, %
187 (56)
95 (58)
200 (54)
105 (57)
0
144 (44)
68 (42)
173 (46)
79 (43)
1
Hormone receptor, n (%)
328 (99)
162 (99)
333 (89)
166 (90)
Positive
3 (1)
1 (1)
40 (11)
18 (10)
Negative
Brain metastases at baseline, n (%)
18 (5)
7 (4)
24 (6)
8 (4)
Liver metastases at baseline, n (%)
247 (75)
116 (71)
266 (71)
123 (67)
Lung metastases at baseline, n (%)
98 (30)
58 (36)
120 (32)
63 (34)
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry: ISH, in situ hybridization; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
"Hormone receptor status is based on data collected using the interactive web/voice response system at the time of randomization, which includes misstratified patients.
ASCO 2022 #LBA3 Plenary Session
Daiichi-Sankyo
10View entire presentation